Potassium Ion

Potassium Ion

SCHEMBL1507637

O=C([O-])c1ccccc1C(c1ccc(O)cc1)c1ccc(O)cc1.[K+]

nearest known ligand 0.70

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA

The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.70
GAA P10253 2/20 0.70
KMT2A Q03164 1/20 0.70
TDP1 Q9NUW8 1/20 0.70
KDM4E B2RXH2 1/20 0.44
HPGD P15428 1/20 0.44
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
LIG1 P18858 1/20 0.37
NQO1 P15559 1/20 0.35
FNTA P49354 1/20 0.34
FNTB P49356 1/20 0.34
LMNA P02545 1/20 0.34
CES2 O00748 1/20 0.33
MGAM O43451 1/20 0.33
SI P14410 1/20 0.33
MGAM2 Q2M2H8 1/20 0.33
PKLR P30613 1/20 0.33
ESR1 P03372 1/20 0.33
ESR2 Q92731 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29636490 0.82 ALDH1A1 (1.00) ALDH1A1GAAKMT2ATDP1KDM4E
SCHEMBL438546 0.82 ALDH1A1 (1.00) ALDH1A1GAAKMT2ATDP1KDM4E
SCHEMBL1507640 0.81 ALDH1A1 (0.96) ALDH1A1GAAKMT2ATDP1KDM4E
Phenol SCHEMBL1068767 0.81 ALDH1A1 (0.96) ALDH1A1GAAKMT2ATDP1KDM4E
SCHEMBL10031846 0.77 TDP1 (0.66) ALDH1A1GAAKMT2ATDP1KDM4E
SCHEMBL10001166 0.77 ALDH1A1 (0.66) ALDH1A1GAAKMT2ATDP1KDM4E
SCHEMBL1758062 0.77 TDP1 (0.64) ALDH1A1GAAKMT2ATDP1KDM4E
SCHEMBL16018458 0.76 ALDH1A1 (0.84) ALDH1A1GAAKMT2ATDP1KDM4E
SCHEMBL19474859 0.76 KMT2A (0.69) ALDH1A1GAAKMT2ATDP1KDM4E
Zinc Ion SCHEMBL11474080 0.75 ALDH1A1 (0.50) ALDH1A1GAAKMT2ATDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2305246-B1 Tumor necrosis factor inhibitors UNIV PENNSYLVANIA (US) 2015-08-26 EP disclosed
US-9096607-B2 Tumor necrosis factor inhibitors THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2015-08-04 US disclosed
US-20140256803-A1 TUMOR NECROSIS FACTOR INHIBITORS THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2014-09-11 US disclosed
US-8765810-B2 Tumor necrosis factor inhibitors THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2014-07-01 US disclosed
US-20130072562-A1 TUMOR NECROSIS FACTOR INHIBITORS CEPHALON, INC. (US) 2013-03-21 US disclosed
US-8318699-B2 Tumor necrosis factor inhibitors THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2012-11-27 US disclosed
EP-2305246-A1 Tumor necrosis factor inhibitors Ception Therapeutics, Inc. (US) 2011-04-06 EP disclosed
EP-2298295-A1 Tumor necrosis factor inhibitors Ception Therapeutics, Inc. (US) 2011-03-23 EP disclosed
US-20090221527-A1 TUMOR NECROSIS FACTOR INHIBITORS CEPTION THERAPEUTICS, INC. (US) 2009-09-03 US disclosed
EP-1845970-A4 TUMOR NECROSIS FACTOR INHIBITORS CEPTION THERAPEUTICS INC (US) 2009-02-18 EP disclosed
EP-1845970-A2 TUMOR NECROSIS FACTOR INHIBITORS Ception Therapeutics, Inc. (US) 2007-10-24 EP disclosed
WO-2006083970-A2 TUMOR NECROSIS FACTOR INHIBITORS CEPTION THERAPEUTICS, INC. (US) 2006-08-10 WO disclosed
WO-2006083869-A2 TUMOR NECROSIS FACTOR INHIBITORS CEPTION THERAPEUTICS, INC. (US) 2006-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221527-A1 TUMOR NECROSIS FACTOR INHIBITORS TNFRSF1A, TNF, TNFRSF9 ALDH1A1 3912/4885GAA 1674/4885KMT2A 4709/4885
US-20140256803-A1 TUMOR NECROSIS FACTOR INHIBITORS TNFRSF1A, TNF, TNFRSF9 ALDH1A1 3912/4885GAA 1674/4885KMT2A 4709/4885
US-20130072562-A1 TUMOR NECROSIS FACTOR INHIBITORS TNFRSF1A, TNF, TNFRSF9 ALDH1A1 3912/4885GAA 1674/4885KMT2A 4709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.